SCHEMBL140664

SCHEMBL140664

CC(C)=C(N)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.48
RECQL P46063 2/20 0.48
TSHR P16473 2/20 0.48
POLB P06746 2/20 0.48
F2 P00734 1/20 0.48
F10 P00742 1/20 0.48
F12 P00748 1/20 0.48
F7 P08709 1/20 0.48
F3 P13726 1/20 0.48
PKM P14618 1/20 0.48
CYP3A4 P08684 1/20 0.48
PARP1 P09874 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C19 P33261 1/20 0.48
PMP22 Q01453 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NOS3 P29474 2/20 0.44
NOS1 P29475 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12262965 0.83 BLM (0.48) BLMRECQLTSHRPOLBF2
SCHEMBL9250790 0.83 BLM (0.48) BLMRECQLTSHRPOLBF2
SCHEMBL38341 0.82 BLM (0.58) BLMRECQLTSHRPOLBF2
SCHEMBL1766180 0.82 BLM (0.58) BLMRECQLTSHRPOLBF2
SCHEMBL1282296 0.82 BLM (0.58) BLMRECQLTSHRPOLBF2
SCHEMBL3149795 0.81 ESR1 (0.46) BLMRECQLTSHRPOLBF2
SCHEMBL6255440 0.81 ESR1 (0.46) BLMRECQLTSHRPOLBF2
SCHEMBL1774314 0.79 BLM (0.55) BLMRECQLTSHRPOLBF2
SCHEMBL30465109 0.79 BLM (0.55) BLMRECQLTSHRPOLBF2
Hydrochloric Acid SCHEMBL4620960 0.79 BLM (0.60) BLMRECQLTSHRPOLBF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022087456-A1 NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-04-28 WO disclosed
EP-3663283-B1 CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THIN FILM FORMED FROM THE COMPOSITION SAMSUNG DISPLAY CO LTD (KR) 2021-11-03 EP disclosed
EP-2460805-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION Oncotherapy Science, Inc. (JP) 2012-06-06 EP disclosed
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION ONCOTHERAPY SCIENCE, INC. (JP) 2012-03-08 US disclosed
EP-2215092-B1 SUBSTITUTED PIPERIDINO-DIHYDROTHIENOPYRIMIDINES BOEHRINGER INGELHEIM INT (DE) 2012-01-25 EP disclosed
US-4898915-A ACRYLIC ESTERS, NITRILES OR ACIDS COMONOMERS WITH VINYL IMIDES; DEPROTECTING WITH HYDRAZINE ANTISTATIC, THICKENERS UNIVERSITY OF AKRON (US) 1990-02-06 US disclosed
EP-0084783-A1 Process for preparing N-isopropylidene amines BAYER AG (DE) 1983-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION NR0B1, GRK7, NR5A2 BLM 3366/4885RECQL 3164/4885TSHR 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.